Targeted therapies for hepatocellular carcinoma

Jonas W. Feilchenfeldt, Eileen M. O'Reilly, Costantine Albany, Ghassan K. Abou-Alfa

Research output: Chapter in Book/Report/Conference proceedingChapter


The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.

Original languageEnglish (US)
Title of host publicationHepatocellular Carcinoma
Subtitle of host publicationTargeted Therapy and Multidisciplinary Care
PublisherSpringer New York
Number of pages14
ISBN (Print)9781603275217
StatePublished - Dec 1 2011



  • Bevacizumab
  • Erlotinib
  • HCC etiology
  • HCC targeted therapies
  • Sorafenib
  • Sunitinib
  • Tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feilchenfeldt, J. W., O'Reilly, E. M., Albany, C., & Abou-Alfa, G. K. (2011). Targeted therapies for hepatocellular carcinoma. In Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care (pp. 355-368). Springer New York.